Clinical trial application submitted to the US FDA for ASC39 oral tablets for the treatment of obesity.
October 26, 2026
Source: drugdu
27
People's Finance News, October 26th - Ascletis Pharma announced on the Hong Kong Stock Exchange that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its ASC39 oral tablets. ASC39 is an oral, small-molecule selective amylin receptor agonist used to treat obesity. The company expects to initiate a Phase I trial in the fourth quarter of 2026.
Source: https://finance.eastmoney.com/a/202610263907436177.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Rotigotine Transdermal Patch Receives Drug Registration Certificate, Expanding Its Parkinson’s Treatment Portfolio October 26, 2026
- Qilu Pharmaceutical’s Changqiping® inhaled spray approved for market launch, adding a new option for maintenance treatment of COPD October 26, 2026
- First generic version of a novel pulmonary arterial hypertension treatment drug approved for marketing. October 26, 2026
- Another global medical device giant has officially announced its spin-off! October 26, 2026
- Nobel Prize-winning company lays off 90% of its staff October 26, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
